Delivery of therapeutic proteins into the nervous system
- Quantitative assessment of the permeability of peptides and proteins at the blood-brain barrier and blood-nerve barrier.
- Protein modifications to increase permeability at the blood-brain barrier and blood-nerve barrier: glycation, polyamine modification (putrescine, spermine, spermidine), ubiquitin modification.
- Delivery of therapeutic proteins across the blood-brain/nerve barriers after systemic administration for the treatment of neurodegenerative diseases.
- Proteins targeted for delivery: neurotrophic factors, anti-oxidant enzymes (superoxide dismutase, catalase), leptin, peptides that inhibit amyloidogenesis, interferons, cytokines, antibodies, interleukins, etc.
- In vivo targeting of Alzheimer's amyloid plaques for diagnostic imaging.
- Pre-clinical animal models to demonstrate efficacy of our delivery technology include:
|Transgenic mouse model of FALS with a point mutation of Gly 93 Ala in SOD
|Transgenic mouse models of Alzheimer's disease that overexpress human A βprotein
||Peptides that inhibit amyloidogenesis, antioxidant enzymes, antibodies to A β
|Diabetic neuropathy: Modulation of DRG trkA and p75 NGF receptors after peripheral axotomy
|Four-vessel occlusion model of cerebral ischemia (stroke)
See my publications
- Professor of Neurology
- Post Doctoral Fellowship - National Multiple Sclerosis Society National Institutes of Health
- PhD - Biochemistry (Neurological Sciences) University of Pennsylvania
- Predoctoral Fellowship - (USPHSG), Institute of Neurological Sciences University of Pennsylvania
- BA - Chemistry College of Wooster
- Research Training Department of Neurology, Albert Einstein College of Medicine